facebook
twitter
rss
account
search
search
 

FDA committee advises approval of Breo, a COPD drug

April 18, 2013 at 12:25 AM   |   Comments

WASHINGTON, April 18 (UPI) -- The U.S. Food and Drug Advisory Committee recommended approval of Breo Ellipta for the treatment of chronic obstructive pulmonary disease, officials say.

GlaxoSmithKline and Theravance Inc. said the Pulmonary-Allergy Drugs Advisory Committee to the FDA voted the efficacy and safety data providedobstruction in patients with COPD -- 9 for, 4 against.

"We are pleased with the outcome of today's meeting. COPD is a substantial evidence to support approval of Breo Ellipta as a once-daily inhaled treatment for the long-term, maintenance treatment of airflow debilitating and progressive disease. Its symptoms are often severe and can have a huge impact on patients' lives," Patrick Vallance, GSK's president of pharmaceuticals, research and development, said in a statement.

"This positive recommendation is a crucial first step towards making Breo Ellipta available for appropriate COPD patients across the United States. We look forward to a final decision from the FDA later this year."

© 2013 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.
Recommended UPI Stories
Featured UPI Collection
trending
2014: The Year in Music [PHOTOS]

2014: The Year in Music [PHOTOS]

Most Popular
1
Police search for California man with drug-resistant TB
2
New research explains insomnia prevalence among elderly
3
New data shows Melbourne is most well-rested city in the world
4
New research details rare cancer that killed Bob Marley
5
Daughters more likely than sons to care for elder parents
Trending News
Video
x
Feedback